title: E2A-PBX1 fusion in adult acute lymphoblastic leukaemia: biological and clinical features.
abstract: Molecular and cytogenetic studies performed in 305 adult acute lymphoblastic leukaemia (ALL) patients enrolled in the gimema (Gruppo Italiano Malattie EMatologiche dell'Adulto) multicentric protocols identified an E2A-PBX1 fusion and/or t(1;19) in 10 patients (3.3%). All had common ALL, were mostly CyIg+ and were CD34/CD13/CD33-. Nine patients achieved a complete remission (CR); five patients showed a haematological relapse after 7 months (median). Four patients are alive in first CR with a median follow-up of 29 months; three patients are molecularly negative. This abnormality is frequently associated with early treatment failure. E2A-PBX1+ adult ALL should be considered for intensified treatment strategies and monitoring of minimal residual disease.
authors.affiliation: Dipartimento di Biotecnologie Cellulari ed Ematologia, University La Sapienza, Rome, Italy. rfoa@bce.uniroma1.it
authors.forename: Robin
authors.initials: R
authors.lastname: Foa
authors.forename: Antonella
authors.initials: A
authors.lastname: Vitale
authors.forename: Marco
authors.initials: M
authors.lastname: Mancini
authors.forename: Antonio
authors.initials: A
authors.lastname: Cuneo
authors.forename: Cristina
authors.initials: C
authors.lastname: Mecucci
authors.forename: Loredana
authors.initials: L
authors.lastname: Elia
authors.forename: Romina
authors.initials: R
authors.lastname: Lombardo
authors.forename: Giuseppe
authors.initials: G
authors.lastname: Saglio
authors.forename: Giuseppe
authors.initials: G
authors.lastname: Torelli
authors.forename: Luciana
authors.initials: L
authors.lastname: Annino
authors.forename: Giorgina
authors.initials: G
authors.lastname: Specchia
authors.forename: Eugenio
authors.initials: E
authors.lastname: Damasio
authors.forename: Anna
authors.initials: A
authors.lastname: Recchia
authors.forename: Francesco
authors.initials: F
authors.lastname: Di Raimondo
authors.forename: Enrica
authors.initials: E
authors.lastname: Morra
authors.forename: Ettore
authors.initials: E
authors.lastname: Volpe
authors.forename: Agostino
authors.initials: A
authors.lastname: Tafuri
authors.forename: Paola
authors.initials: P
authors.lastname: Fazi
authors.forename: Stephen P
authors.initials: SP
authors.lastname: Hunger
authors.forename: Franco
authors.initials: F
authors.lastname: Mandelli
mesh_terms: D000293:Adolescent; D000328:Adult; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D002878:Chromosomes, Human, Pair 1 / Q000235:genetics; D002888:Chromosomes, Human, Pair 19 / Q000235:genetics; D005260:Female; D005500:Follow-Up Studies; D018398:Homeodomain Proteins / Q000235:genetics*; D006801:Humans; D007621:Karyotyping; D008297:Male; D008875:Middle Aged; D015514:Oncogene Proteins, Fusion / Q000235:genetics*; D054198:Precursor Cell Lymphoblastic Leukemia-Lymphoma / Q000188:drug therapy / Q000235:genetics*; D011379:Prognosis; D012008:Recurrence; D014178:Translocation, Genetic; D017211:Treatment Failure
chemical_list: D018398:Homeodomain Proteins; D015514:Oncogene Proteins, Fusion; C089847:E2A-Pbx1 fusion protein